Chronic lymphocytic leukemic patients, resistant to chemotherapy.

Med Hypotheses

Research Service, VA Hospital, Elmhurst, IL 60126.

Published: August 1988

In four reported studies, intensive chemotherapy of various types was administered to large groups of patients with chronic lymphocytic leukemia (CLL) in advanced stages. About half of the patients were non-responders to the therapy. Resistance to therapy was also found in 12% of patients with early CLL and in 19 CLL patients who had in vitro radioresistant lymphocytes before therapy. The findings support the hypothesis of the heterogeneity of CLL patients and suggest the need for new methods for therapy of non-responders and for in vitro or in vivo tests to diagnose non-responders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0306-9877(88)90123-5DOI Listing

Publication Analysis

Top Keywords

chronic lymphocytic
8
cll patients
8
patients
6
lymphocytic leukemic
4
leukemic patients
4
patients resistant
4
resistant chemotherapy
4
chemotherapy reported
4
reported studies
4
studies intensive
4

Similar Publications

Purpose: The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a newly developed biomarker that combines measurements of CRP, serum albumin, and lymphocyte count. This index provides a thorough assessment of a patient's inflammation level, nutritional condition, and immunological function. The objective of this study is to examine the correlation between the CALLY index and all-cause mortality in COPD patients.

View Article and Find Full Text PDF

Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity.

Clin Cosmet Investig Dermatol

January 2025

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Lymphomatoid papulosis (LyP) is currently categorized as a primary lymphoproliferative disorder that follows a chronic, recurrent clinical course. The diagnosis of LyP is mainly based on clinical presentation and histopathological correlation. Six subtypes of LyP have been described and recognized, each with different histological features and sometimes distinct clinical presentations.

View Article and Find Full Text PDF

Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis.

Front Immunol

January 2025

State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.

Background: Telitacicept, a new biological agent, was approved in China for treating systemic lupus erythematosus (SLE) in 2021. Its optimal dosing for treating SLE remains unclear. Therefore, the aim of this meta-analysis is to evaluate the efficacy and safety of various telitacicept doses in SLE treatment.

View Article and Find Full Text PDF

Background: Lactate has long been recognized as a key prognostic biomarker in sepsis. Similarly, the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) has been investigated in various conditions, including sepsis. Previous studies have explored the optimal NLR cutoff to differentiate sepsis survivors from nonsurvivors, predict bacteremia, diagnose sepsis, and assess mortality.

View Article and Find Full Text PDF

Objectives: Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe coronavirus disease 2019 (COVID-19) as well as impaired responses to COVID-19 vaccination, which may be overcome by repeated booster vaccinations. Our objective was to explore the uptake of the COVID-19 vaccine in this population since records of this are scarce.

Methods: In this nationwide cohort study, we used multiple population-based health and sociodemographic registries to study COVID-19 vaccine uptake in individuals with CLL in Sweden, from 27 December 2020 to 28 February 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!